• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.

作者信息

Meyer Anja, Wittekind Paula S, Kotschenreuther Konstantin, Schiller Joanna, von Tresckow Julia, Haak Thomas H, Kofler David M

机构信息

Department I of Internal Medicine, University of Cologne, Cologne, Germany.

Department I of Internal Medicine, University of Cologne, Cologne, Germany

出版信息

Ann Rheum Dis. 2021 Dec;80(12):e196. doi: 10.1136/annrheumdis-2019-216576. Epub 2019 Nov 19.

DOI:10.1136/annrheumdis-2019-216576
PMID:31744827
Abstract
摘要

相似文献

1
Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.类风湿关节炎患者体内的调节性T细胞频率可通过传统和生物性改善病情抗风湿药升高，但JAK抑制剂无此作用。
Ann Rheum Dis. 2021 Dec;80(12):e196. doi: 10.1136/annrheumdis-2019-216576. Epub 2019 Nov 19.
2
Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer .
Ann Rheum Dis. 2021 Dec;80(12):e197. doi: 10.1136/annrheumdis-2019-216598. Epub 2020 Jan 21.
3
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.最新进展：类风湿关节炎获批和新兴 JAK 抑制剂。
Expert Opin Pharmacother. 2021 Feb;22(2):205-218. doi: 10.1080/14656566.2020.1822325. Epub 2020 Sep 23.
4
JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.JAK-STAT 抑制剂：类风湿关节炎治疗管理的浸入式治疗方法。
Int Immunopharmacol. 2020 Sep;86:106731. doi: 10.1016/j.intimp.2020.106731. Epub 2020 Jun 23.
5
Patients' safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire.使用生物制剂和JAK抑制剂对患者安全技能的评估：BioSecure问卷的更新
Joint Bone Spine. 2021 Oct;88(5):105215. doi: 10.1016/j.jbspin.2021.105215. Epub 2021 May 14.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略：2019 年更新版（使用合成和生物疾病修正抗风湿药物）
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
7
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.类风湿关节炎患者心血管系统中 Janus 激酶（JAK）抑制剂的临床方面。
Int J Mol Sci. 2020 Oct 7;21(19):7390. doi: 10.3390/ijms21197390.
8
[Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].[类风湿关节炎的药物治疗：生物制剂和新型合成改善病情抗风湿药目前处于什么地位？]
Inn Med (Heidelb). 2023 Oct;64(10):1005-1012. doi: 10.1007/s00108-023-01554-6. Epub 2023 Jul 26.
9
Clinical significance of Janus Kinase inhibitor selectivity.Janus 激酶抑制剂选择性的临床意义。
Rheumatology (Oxford). 2019 Jun 1;58(6):953-962. doi: 10.1093/rheumatology/key339.
10
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis and Baseline Signaling Profile Associates With Treatment Response.托法替尼抑制类风湿关节炎中的几个 JAK-STAT 通路，且基线信号特征与治疗反应相关。
Front Immunol. 2021 Sep 24;12:738481. doi: 10.3389/fimmu.2021.738481. eCollection 2021.

引用本文的文献

1
Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation.类风湿关节炎的分子氢疗法：改善甲氨蝶呤诱导的骨髓抑制和免疫调节的病例报告
In Vivo. 2025 Jul-Aug;39(4):2186-2195. doi: 10.21873/invivo.14014.
2
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition.微调系统性红斑狼疮治疗：选择性酪氨酸激酶2抑制的潜力
RMD Open. 2024 Dec 31;10(4):e005072. doi: 10.1136/rmdopen-2024-005072.
3
The 'T paradox' in inflammatory arthritis.炎症性关节炎中的“T悖论”。
Nat Rev Rheumatol. 2025 Jan;21(1):9-21. doi: 10.1038/s41584-024-01190-w. Epub 2024 Dec 9.
4
Evaluation of CD4 CD25 CD127 Regulatory T-Cells in Different Stages of Psoriatic Arthritis Patients.银屑病关节炎患者不同阶段CD4 CD25 CD127调节性T细胞的评估
Adv Biomed Res. 2024 Sep 23;13:77. doi: 10.4103/abr.abr_359_23. eCollection 2024.
5
Endogenous Melanin and Hydrogen-Based Specific Activated Theranostics Nanoagents: A Novel Multi-Treatment Paradigm for Rheumatoid Arthritis.内源性黑色素和基于氢的特异性激活治疗性纳米制剂：类风湿性关节炎的一种新的多治疗模式。
Adv Sci (Weinh). 2024 Jul;11(25):e2401046. doi: 10.1002/advs.202401046. Epub 2024 Apr 26.
6
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis.白介素-6 信号抑制对类风湿关节炎中 Treg 亚群的影响及 Tregs 与临床结局的关系。
Rheumatology (Oxford). 2024 Sep 1;63(9):2515-2524. doi: 10.1093/rheumatology/keae196.
7
Th17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment.在多关节型幼年特发性关节炎患者中可检测到Th17/1细胞和既往Th17细胞，且在治疗后数量增加。
Pediatr Rheumatol Online J. 2024 Mar 2;22(1):32. doi: 10.1186/s12969-024-00965-5.
8
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response.类风湿关节炎中CD39和CD73表达的改变：对疾病活动度和治疗反应的影响
Biomolecules. 2023 Dec 19;14(1):1. doi: 10.3390/biom14010001.
9
Regulatory T cells in peripheral tissue tolerance and diseases.外周组织耐受和疾病中的调节性 T 细胞。
Front Immunol. 2023 May 1;14:1154575. doi: 10.3389/fimmu.2023.1154575. eCollection 2023.
10
CD8 Regulatory T Cell Deficiency in Elderly-Onset Rheumatoid Arthritis.老年起病类风湿关节炎中的CD8调节性T细胞缺陷
J Clin Med. 2023 Mar 17;12(6):2342. doi: 10.3390/jcm12062342.